LRRN1: A Non-Coding RNA Molecule as A Potential Drug Target Or Biomarker

Target Name: LRRN1

NCBI ID: G57633

LRRN1

LRRN1: A Non-Coding RNA Molecule as A Potential Drug Target Or Biomarker

LRRN1 (Long non-coding RNA 1) is a gene that has been identified as a potential drug target or biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. LRRN1 is a non-coding RNA molecule that has been shown to play a role in regulating gene expression and has been associated with the development and progression of various diseases.

The LRRN1 gene is located on chromosome 6p21 and has been shown to encode a protein that is involved in the regulation of gene expression. LRRN1 has been shown to play a role in the regulation of stem cell proliferation and has been associated with the development of cancer.

LRRN1 has also been shown to be involved in the regulation of neural cell survival and has been associated with the development of neurodegenerative diseases. For example, studies have shown that LRRN1 is expressed in the brains of individuals with Alzheimer's disease and that its expression is associated with the severity of the disease.

LRRN1 has also been shown to be involved in the regulation of immune cell function and has been associated with the development of autoimmune disorders. For example, studies have shown that LRRN1 is expressed in the T cells of individuals with rheumatoid arthritis and that its expression is associated with the severity of the disease.

In conclusion, LRRN1 is a gene that has been identified as a potential drug target or biomarker in a variety of diseases. Further research is needed to fully understand the role of LRRN1 in these diseases and to develop effective treatments.

Protein Name: Leucine Rich Repeat Neuronal 1

The "LRRN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets